Pfizer announced that the FDA has approved Velsipity, an oral, once-daily, selective sphingosine-1-phosphate, or S1P receptor modulator for adults with moderately to severely active ulcerative colitis, or UC. The approved recommended dose for Velsipity is 2 mg.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PFE:
- Pfizer (NYSE:PFE) Bags Approval for 2 Drugs
- Pfizer (NYSE:PFE) Down despite Hefty Number of COVID-19 Shots
- Pfizer call volume above normal and directionally bullish
- Pfizer announces FDA approval of BRAFTOVI + MEKTOVI
- Pfizer price target lowered to $36 from $39 at JPMorgan
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue